Construction of a Prospective Cohort Database for the Perioperative Period of Cardiac Surgery

Condition(s) studied

Investigational drug(s) / intervention(s)

Cardiac surgey: Cardiac surgey

Study summary

Cardiovascular disease (CVD) is the leading cause of global morbidity and mortality, with its prevalence increasing significantly from 1990 to 2019. Establishing a comprehensive cardiac surgery database is crucial for exploring perioperative prognostic factors and improving clinical outcomes.

This muti-center, prospective observational study aims to construct a prospective cohort database for perioperative cardiac surgery. We plan to enroll adult patients who undergo cardiac surgery with cardiopulmonary bypass at the Second Affiliated Hospital of Zhejiang University and other hospitals from May 1, 2026 to December 31, 2031. Multi-dimensional perioperative data, including laboratory tests, hemodynamics, intraoperative echocardiography, and perioperative medications, will be collected and integrated, along with epidemiological data, clinical diagnosis and treatment information, multimodal data, and follow-up outcomes. An interconnected big data sharing platform will also be built.

This database will provide a valuable resource for multi-level researches such as perioperative risk assessment, individualized prevention, precise diagnosis and treatment, and therapeutic efficacy monitoring. It will also help optimize surgical and perioperative management, improve the quality of cardiac surgery, and provide evidence for the refinement of China's healthcare system, ultimately enhancing perioperative safety and rehabilitation efficiency of patients.

Eligibility

Primary outcome measure(s)

• Incidence of major adverse cardiac and cerebrovascular events (MACCE) — 4, 12 weeks and 1years after surgery
  Myocardial infarction; New-onset stroke: new irreversible neurological impairment confirmed by radiological examination or autopsy showing a new cerebral lesion; Death
• Incidence of Perioperative Transfusion of Allogeneic Blood Products — 30 days after surgery
  Allogeneic red blood cells, plasma, platelets, and blood coagulation factors
• Amount of Allogeneic Blood Products Transfused During the Perioperative Period — 30 days after surgery
  Allogeneic red blood cells, plasma, platelets, and blood coagulation factors

Trial sites (1)

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Other trials for the same condition